Like a mentor helping medical students choose between specialties, a protein complex helps shape the destiny of developing T cells, St. Jude Children’s Research Hospital scientists have reported. The research appears today in the journal Science Immunology and adds to growing evidence of the critical role cell metabolism plays in the immune system.
The protein complex is mTORC1, which regulates cell growth and metabolism. St. Jude immunologists found mTORC1 acts in response to cues from in and around developing T cells and intersects with metabolic activity, to influence whether the cells become conventional or unconventional T cells. To their surprise, researchers found that disrupting mTORC1 led to metabolic changes that favored development of unconventional T cells at the expense of conventional T cells.
The research comes amid excitement about harnessing the immune system to fight cancer, tame autoimmune diseases and combat infectious diseases.
“We know that conventional and unconventional T cells are fundamentally different,” said corresponding author Hongbo Chi, Ph.D., a member of the St. Jude Department of Immunology faculty. “They express different cell surface receptors. The cells have different functions. But until now the mechanism that helps decide their fates has remained largely unknown.”
T cells play a central role in the adaptive immune system, functioning like elite commando units trained to find and eliminate specific viruses and other threats. T cell development occurs in the thymus after immature (precursor) cells in the bone marrow travel there to mature and specialize. Their specialty is signaled partly by protein receptors on the cell surface known as T cell receptors (TCRs) or antigen receptors. T cells depend on the T cell receptors to recognize targets and respond to changing conditions.
In humans, the vast majority of T cell receptors have an alpha (α) protein chain and a beta (β) chain. These are conventional T cells that circulate widely and reside in the spleen and lymph nodes. A smaller number of T cells carry receptors made from a gamma (γ) and a delta (δ) protein chain. They belong to the family of unconventional T cells that are found in the gut, skin and other barrier tissues.
Working with mouse models and developing T cells in the laboratory, Chi and his colleagues showed that activation of mTORC1 revs up energy production through glycolysis and oxidation to fuel anabolic metabolism and promote development of αβ T cells.
When investigators disabled mTORC1, metabolism was disrupted, which was associated with a reduction in the αβ T cells and an increase in γδ T cells.
Deleting a key component of mTORC1, a protein called RAPTOR, disabled mTORC1 and altered the metabolic balance in developing T cells. The change reduced anabolic metabolism but increased levels of toxic molecules called reactive oxygen species (ROS) and upregulated activity along a molecular pathway that promotes cell growth.
The change enhanced development of γδ T cells in the thymus and hindered development of αβ T cells.
Researchers also reported expression of signature genes associated with γδ T cells was enhanced in mice when RAPTOR was deleted from the mTORC1 complex.
“This research establishes mTORC1-driven metabolic signaling as a decisive factor in determining the fate of developing T cells and suggests metabolic processes are a fundamental mechanism that connects external signals with internal processes to guide the fate of immune cells,” Chi said.
The first authors are Daniel Bastardo Blanco and Xiang Chen of St. Jude and Kai Yang, formerly of St. Jude. The other authors are Pradyot Dash, Geoffrey Neale, Celeste Rosencrance, John Easton, Wenan Chen, Changde Cheng, Yogesh Dhungana, Anil KC, Walid Awad, Xi-Zhi Guo and Paul Thomas, all of St. Jude.
The research was funded in part by grants (AI101407, AI105887, CA176624, CA221290, NS064599, AI107625, AI121832, CA021765) from the National Institutes of Health; the Arthritis National Research Foundation and ALSAC, the fundraising and awareness organization of St. Jude.
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital is leading the way the world understands, treats and cures childhood cancer and other life-threatening diseases. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20 percent to 80 percent since the hospital opened more than 50 years ago. St. Jude freely shares the breakthroughs it makes, and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children. Families never receive a bill from St. Jude for treatment, travel, housing and food — because all a family should worry about is helping their child live. To learn more, visit stjude.org or follow St. Jude on social media at @stjuderesearch.